Seres Therapeutics (NASDAQ:MCRB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Other equities research analysts have also issued reports about the company. Oppenheimer set a $16.00 target price on Seres Therapeutics and gave the stock a “buy” rating in a research report on Friday, November 9th. Cantor Fitzgerald set a $15.00 target price on Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, November 8th. ValuEngine raised Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, November 6th. Chardan Capital reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Sunday, October 28th. Finally, BidaskClub raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Seres Therapeutics has an average rating of “Hold” and an average target price of $13.81.

Shares of Seres Therapeutics stock opened at $8.09 on Wednesday. The firm has a market cap of $343.19 million, a PE ratio of -3.66 and a beta of 0.61. The company has a current ratio of 2.04, a quick ratio of 2.04 and a debt-to-equity ratio of 0.85. Seres Therapeutics has a 12-month low of $5.64 and a 12-month high of $11.35.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.03. The company had revenue of $9.06 million for the quarter, compared to analyst estimates of $23.43 million. Seres Therapeutics had a negative return on equity of 1,584.66% and a negative net margin of 515.16%. Equities research analysts predict that Seres Therapeutics will post -2.41 EPS for the current fiscal year.

In other news, insider John G. Aunins sold 42,837 shares of Seres Therapeutics stock in a transaction on Monday, September 17th. The stock was sold at an average price of $7.64, for a total transaction of $327,274.68. Following the transaction, the insider now owns 146,648 shares in the company, valued at $1,120,390.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Roger Pomerantz sold 12,518 shares of Seres Therapeutics stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $9.10, for a total value of $113,913.80. Following the transaction, the insider now owns 218,799 shares in the company, valued at approximately $1,991,070.90. The disclosure for this sale can be found here. Insiders have sold 69,634 shares of company stock worth $526,006 in the last quarter. 37.10% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Seres Therapeutics during the second quarter valued at $117,000. Citadel Advisors LLC grew its holdings in shares of Seres Therapeutics by 48.0% during the third quarter. Citadel Advisors LLC now owns 31,400 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 10,183 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Seres Therapeutics by 175.0% during the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock valued at $314,000 after buying an additional 23,222 shares in the last quarter. Chicago Equity Partners LLC purchased a new position in shares of Seres Therapeutics during the second quarter valued at $415,000. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Seres Therapeutics by 18.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock valued at $1,009,000 after buying an additional 18,562 shares in the last quarter. Institutional investors and hedge funds own 77.86% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Featured Story: Understanding debt-to-equity ratio in fundamental analysis

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.